Episode 1:

Focus: Who signed, what drugs are included, and why it matters

This episode identifies the drug manufacturers that entered into pricing agreements with the Trump administration and outlines the specific drugs covered under those arrangements. It explains the intent behind these agreements, the pricing concessions involved, and how these decisions directly impact patient affordability, access, and out-of-pocket costs. The discussion also highlights early implications for provider reimbursement and financial counseling workflows.

Key takeaway: Not all drugs or manufacturers are affected equally—and understanding which ones are included is critical for patient advocacy and revenue planning.